PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
152 hedge funds and large institutions have $329M invested in PDL BioPharma, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 56 reducing their positions, and 25 closing their positions.
476% more call options, than puts
Call options by funds: $334K | Put options by funds: $58K
11% more capital invested
Capital invested by funds: $297M → $329M (+$31.9M)
7% less funds holding
Funds holding: 163 → 152 (-11)
30% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 56
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$13.1M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$8.99M |
| 3 |
AC
Armistice Capital
New York
|
+$4.42M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.65M |
| 2 |
BlackRock
New York
|
-$3.69M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.43M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.17M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.95M |
PDLI Hedge Fund Activity: Q3 2018 in Review
152 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2018, worth a combined $329M — up 11% from $297M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PDLI and 15 opened new positions — a net loss of 10 holders — while 56 trimmed existing stakes and 39 added.
The largest buyer was Kennedy Capital Management, adding an estimated $13.1M. The largest seller was Vanguard Group, cutting an estimated $6.65M.
- 152 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2018, down from 163 in Q2 2018.
- Funds reported $329M of PDL BioPharma, Inc. stock for Q3 2018, up 11% quarter-over-quarter.
- 15 funds opened new PDL BioPharma, Inc. positions in Q3 2018 and 25 closed out, a net change of -10 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2018 was Kennedy Capital Management, an estimated $13.1M added.
- The largest PDL BioPharma, Inc. seller in Q3 2018 was Vanguard Group, an estimated $6.65M sold.
Based on aggregated 13F filings for Q3 2018.